Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells (Q39241674)

10 September 2017

title

Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells (English)

1 reference

10 September 2017

1 reference

1 reference

1 reference

Alan Richardson

4

0 references

author name string

Vasileios A Stamelos

series ordinal

1

1 reference

10 September 2017

Elizabeth Robinson

series ordinal

2

1 reference

10 September 2017

Charles W Redman

series ordinal

3

1 reference

10 September 2017

language of work or name

English

0 references

publication date

17 November 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

128

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

377-382

1 reference

The biology of ovarian cancer: new opportunities for translation

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Bcl-2 proteins and mitochondria—Specificity in membrane targeting for death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line--a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Establishment and characterization of multicellular spheroids from a human glioma cell line; Implications for tumor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2012.11.019

1 reference

10 September 2017

1 reference